The 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012)

TheBody.com/TheBodyPRO.com covers The 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012)

HIV Status Tied to Greater Risk of Death Following Heart Attack, Large Examination of Hospital Records Finds

HIV-infected people who are hospitalized with acute myocardial infarction (AMI) are significantly more likely to die than their HIV-uninfected counterparts, U.S. researchers have found. The findings add to the growing body of evidence suggesting that close monitoring of cardiovascular health is particularly important for people living with HIV.

More Highlights:

TheBodyPRO.com's independent coverage of ICAAC 2012 is not associated with the conference itself. Please note that all links on this page will take you to articles on TheBodyPRO.com, TheBody.com's sister site for health care professionals.

TheBodyPRO.com is an independent website not associated with this conference.

The 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) is expected to draw approximately 10,000 attendees, most of them clinicians and researchers, from throughout the world to present and discuss the latest developments in infectious disease etiology, epidemiology and clinical management. Although it is not an HIV-specific conference, studies on HIV and related complications/coinfections often make up a significant proportion of the conference's presentations.

For more information on ICAAC 2012, please visit the conference's website. You may also view the conference online program planner.

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Home

All Headlines

Previous Conferences

Drug News From ICAAC
Reyataz and Kidney Stones
Zinc Finger Gene Therapy Continues to Show Promise
Once-Daily Pills Improve Outcomes
Long-Acting Drug in Development
More >>

TheBodyPRO.com is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.